{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,15]],"date-time":"2026-08-15T05:35:22Z","timestamp":1786772122020,"version":"build-2736575974"},"reference-count":5,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Canc Conf J"],"DOI":"10.1007\/s13691-026-00877-z","type":"journal-article","created":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T15:26:23Z","timestamp":1782919583000},"page":"439-442","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["A case of Large Cell Neuroendocrine Carcinoma (LCNEC) treated with tarlatamab"],"prefix":"10.1007","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-6214-3212","authenticated-orcid":false,"given":"Reimi","family":"Mizushima","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makiko","family":"Yomota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoko","family":"Togashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terufumi","family":"Kato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukio","family":"Hosomi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,1]]},"reference":[{"key":"877_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2025.103022","volume":"140","author":"M Alameda-Guijarro","year":"2025","unstructured":"Alameda-Guijarro M, Rueda-Lara A, Martin-Montalvo G et al (2025) Novel therapies targeting delta-like ligand 3 (DLL3) in pulmonary and gastroenteropancreatic neuroendocrine carcinomas. Cancer Treat Rev 140:103022. https:\/\/doi.org\/10.1016\/j.ctrv.2025.103022","journal-title":"Cancer Treat Rev"},{"key":"877_CR2","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1056\/NEJMoa2502099","volume":"393","author":"G Mountzios","year":"2025","unstructured":"Mountzios G, Sun L, Cho BC et al (2025) Tarlatamab in small-cell lung cancer after platinum-based chemotherapy. N Engl J Med 393:349\u2013361. https:\/\/doi.org\/10.1056\/NEJMoa2502099","journal-title":"N Engl J Med"},{"key":"877_CR3","doi-asserted-by":"publisher","first-page":"3021","DOI":"10.1200\/JCO-25-00363","volume":"43","author":"M Wermke","year":"2025","unstructured":"Wermke M, Gambardella V, Kuboki Y et al (2025) Phase I dose-escalation results for the delta-like ligand 3\/CD3 IgG-like T-cell engager obrixtamig (BI 764532) in patients with delta-like ligand 3+ small cell lung cancer or neuroendocrine carcinomas. JCO 43:3021\u20133031. https:\/\/doi.org\/10.1200\/JCO-25-00363","journal-title":"JCO"},{"key":"877_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtocrr.2024.100712","volume":"5","author":"SA Patel","year":"2024","unstructured":"Patel SA, Whang Y, Medley C et al (2024) Tarlatamab for large cell neuroendocrine carcinoma in a young adult: a case report. JTO Clin Res Rep 5:100712. https:\/\/doi.org\/10.1016\/j.jtocrr.2024.100712","journal-title":"JTO Clin Res Rep"},{"key":"877_CR5","doi-asserted-by":"publisher","DOI":"10.1200\/PO-25-00184","author":"E Gariazzo","year":"2025","unstructured":"Gariazzo E, Laaksonen S, Canty S et al (2025) Efficacy and safety of tarlatamab in a patient with advanced delta-like ligand 3-positive large cell neuroendocrine lung carcinoma and untreated brain metastases: a case report. JCO Precis Oncol. https:\/\/doi.org\/10.1200\/PO-25-00184","journal-title":"JCO Precis Oncol"}],"container-title":["International Cancer Conference Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13691-026-00877-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13691-026-00877-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13691-026-00877-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T05:39:54Z","timestamp":1784180394000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13691-026-00877-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,1]]},"references-count":5,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,7]]}},"alternative-id":["877"],"URL":"https:\/\/doi.org\/10.1007\/s13691-026-00877-z","relation":{},"ISSN":["2192-3183"],"issn-type":[{"value":"2192-3183","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,1]]},"assertion":[{"value":"4 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Written informed consent was obtained from the patient for publication of this case report and any accompanying images.","order":2,"name":"Ethics","label":"Consent to publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Tarlatamab therapy was initiated after approval from the institutional ethics committee.","order":3,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}